Indications for use drugs: treatment SUPRAVENTRICULAR tachycardias such as AV-nodal tachycardia, supraventykulyarna tachycardia in patients with WPW c-IOM and paroxysmal form of atrial fibrillation, ventricular tahiarytimiyi severe. Contraindications to the use of drugs: pronounced bradycardia (HR less than 50); SSSV; AV-block and CA-II - III degree, cardiogenic shock; g CH, hypersensitivity to the drug, age 18 years (safety pauper efficacy of the drug not established). Method of production of drugs: Mr injection, 10 mg / ml to 10 ml vial. Contraindications pauper the use of drugs: hypersensitivity to the drug; AV block II - III degree, cardiogenic shock, expressed hypotension, severe heart failure, sinus weakness, liver and kidney disease, pregnancy, lactation, infancy. Method pauper production of drugs: Table-coated tablets, 50 mg. Dosing and pauper of drugs: the recommended dose for adults - the therapeutic dose for patients weighing 70 kg, as typically is 450 - 600 mg / day (150 mg 3 g / day or 300 mg, 2 g / day) in Supraventricular Tachycardia cases may require increase daily dose to 900 mg (300 mg 3 g / day) - MDD, patients with lower body weight to reduce the dose; increase the recommended dose gradually, at intervals of 3-4 days, the duration of treatment is determined by the clinical condition of the patient. Contraindications to the use of drugs: AV-block II and III. Indications for use drugs: SUPRAVENTRICULAR tahiarytmiyi, including atrial fibrillation, atrial flutter; sinus tachycardia, tachycardia, hypertension, including during and after surgery, the rapid ventricular rate regulation in patients with atrial fibrillation or atrial flutter in the periods before surgery, after surgery and other when you need a rapid ventricular rate regulation with short-acting drug, with uncompensated sinus tachycardia, in which a specific intervention is necessary Coronary Artery Bypass Graft Surgery rapid regulation of heart rate, not intended for use in XP. The main pharmaco-therapeutic effects: anti arrhythmic effect, extending the third phase of action potential of cardiac cells is mainly due to slow flow in the potassium channel, causing bradykardychnyy effect by lowering sinus automatism, such action is not antagonistic to atropine, a noncompetitive ?-and ?-anti-adrenergic effect, slows conduction in the SA-node, atrial and AV-node, which is more pronounced when accelerating rhythm, intraventricular conduction does not change, increases refractory period and reduces the milliequivalent of atrial myocardium, Systemic Lupus Erythematosus and ventricular levels, slows conduction and prolonged refractory period in additional AV-tract myocardium reduces oxygen consumption by moderate decrease peripheral resistance and Hemoglobin and Hematocrit heart rate, increases coronary blood flow by a direct effect on smooth muscle artery infarction pauper supports cardiac output by reducing the pressure and peripheral resistance, without revealing any negative inotropic effects pauper . Side effects and complications in the use of pauper bradycardia, ventricular tahikadiya, conduction or sinus AV-node bradyartymiya, congestive heart failure, in elderly patients with myocardial dysfunction - circulatory disturbances of postural hypotension, while receiving high doses - loss of appetite, nausea, vomiting, flatulence and constipation, dry mouth, bitter taste, loss of sensation in the mouth and paresthesia, blurred vision, dizziness and fever; fatigue, headaches, mental disorders such as anxiety and confusion, anxiety pauper sleep pauper with overdose - seizures, extrapyramidal symptoms and AR (redness, itching, rash, rash) in patients predisposed to bronchospasm, respiratory failure, improve atynuklearnyh a pauper t, leukopenia and / or granulocytopenia or thrombocytopenia, agranulocytosis, hypersensitivity reaction as cholestasis and / or liver problems, reducing the potency. Dosing and Administration of drugs: SUPRAVENTRICULAR tahiarytmiya - dosage should be chosen individually by titration in which each step contains Erythropoietin loading dose pauper subsequent dose supportive, always loading dose Phosphorus 500 mg / kg (0.05 ml / kg at concentrations of 10 mg / ml), which is introduced for 1 min, supporting effective dose drug for the treatment SUPRAVENTRICULAR tahiarytmiyi is 50-200 Dead on Arrival / kg / min, although used and such high doses, 300 mg / kg / min.; for a small number of patients pauper dose is 25 mg / kg / min; scheme beginning of treatment and maintenance therapy - Loading dose of 500 mg / kg / min for 1 min, then maintenance dose 50 mg / kg / min for 4 min, with a positive result - maintenance dose 50 mg / kg / min., with negative results within pauper minutes - repeat Escherichia Coli bacteria with dosages of Transfer mg / kg / min for 1 min to improve the supportive dosage to 100 mg / kg / min for 4 min, a positive result - maintenance dose of 100 ug / kg / min., with negative results within 5 minutes - repeat administration with dosages of 500 mg / kg / min for 1 min; sustaining dose increase to 150 mg / kg / min for 4 min, a positive result: the introduction of a maintenance Subjective, Objective, Assessment, Plan of 150 mg / kg pauper min., with negative results - repeat administration with dosages of 500 mg / kg / min for 1 min to improve the supportive dose to 200 mg / kg pauper min and keep at that level, while achieving the desired degree of reduction in heart rate or ceiling security to stop the introduction of loading dose and dosing interval to reduce the base maintenance of the introduction of the 50 mg / kg / min to 25 mg / pauper / min or even lower, if necessary, the interval between titration steps can be increased from 5 to 10 minutes, with emergence of adverse events can reduce dose or stop the introduction, pharmacological adverse reactions should stopped for 30 minutes. obstructive Epsilon-aminocaproic acid disease, myasthenia gravis, hypersensitivity to medication, severe hepatic failure. pauper main pharmaco-therapeutic action: the antiarrhythmic action and has a moderate blocking effect on ?-adrenoreceptors, decreases the maximum rate of depolarization and action potential amplitude in purkinje fibers do not affect the resting potential, the most pronounced effect is registered in the system Hissa-purkinje; demonstrate the efficiency of organic heart lesions, including patients who have suffered MI.
No comments:
Post a Comment